Novel RT-PCR Test Enables Early Detection of Parkinson’s Disease

Parkinson's disease (PD) is a neurological disorder with no known definitive cause, although it is thought that both genetics and environmental factors play a role. There is currently no cure for the disease. When patients begin to show typical signs of PD, a significant loss of dopamine-producing cells has already occurred, making it difficult to halt further brain decline. As the disease advances, problems with movement and speech arise, affecting the individual's independence. For these reasons, genetic testing becomes vital for assessing an individual's risk and for early detection. Identifying specific genetic mutations linked to PD not only helps people make educated healthcare choices but also guides researchers in developing targeted treatments. Understanding these genetic factors can further contribute to personalized treatment strategies, improving patient care.

In the search for early detection methods for PD, accurately identifying the condition has proven to be challenging. Anbio Biotechnology (Frankfurt, Germany) has developed a promising approach using real-time polymerase chain reaction (RT-PCR) technology for early PD detection. Studies have found that early-onset PD is commonly associated with mutations in the GBA and LRRK2 genes. Among these mutations, L444P, G2385R, and R1628P are notably prevalent. To address this, Anbio has introduced its GBA L444P/LRRK2 R1628P/LRRK2 G2385R Gene Mutations Polymorphism Test Kit. This RT-PCR assay is specifically designed to rapidly and accurately identify these three key genetic polymorphisms in the GBA and LRRK2 genes.

The kit employs a highly specialized Taq enzyme and fluorescent probes to enhance detection specificity. Quality control is maintained through the use of internal and multiple positive controls, reducing the chances of false negatives and positives. The test can identify these three specific GBA and LRRK2 genetic polymorphisms in as little as 117 minutes. The procedure is straightforward, and the test results are easy to understand, objective, and reliable. When it comes to accuracy, sensitivity, and specificity, the kit outperforms other similar products available on the market. The findings generated by Anbio's test kit are significant not only for understanding the mechanisms behind PD but also for shaping effective treatment strategies.

Related Links:
Anbio Biotechnology 

Visit expo >

New

Platinum Member

Flu SARS-CoV-2 Combo Test

OSOM® Flu SARS-CoV-2 Combo Test

Magnetic Bead Separation Modules
MAG and HEATMAG

Complement 3 (C3) Test

GPP-100 C3 Kit

Gold Member

Hemoglobin Testing System

VARIANTnbs